| Autor: |
Sa-Sa, Zhang, Yi-Jin, Wu, Shu, Pan, Qi-Hai, Wang, Wen-Gang, Chen, Zhong-Fang, Wang, Jin-Ying, Xu, Jian, Zuo, Qin, Yin |
| Rok vydání: |
2022 |
| Zdroj: |
Immunopharmacology and immunotoxicology. |
| ISSN: |
1532-2513 |
| Popis: |
The first-line anti-rheumatic drug methotrexate (MTX) is used in the combination. Because of the unpredictable adverse reactions, optimization of relevant regimens is necessary and meaningful. This study aimed to study the possible interaction betweenWe established adjuvant-induced arthritis (AIA) model, which was treated with MTX and MTX + xanthone-rich fraction (XRF). The clinical efficacy was evaluated by histopathological examination, and LC-MS was used to monitor the blood concentration of MTX. Western blotting and immunohistochemistry were used to detect protein expression.Compared with MTX-treated rats, inflammation in the immunized rats in the MTX + XRF group was obvious, indicating that XRF antagonized the anti-rheumatic effect of MTX. Meanwhile, XRF reduced liver and kidney injuries caused by MTX in addition to MTX. Results from immunohistochemical and nappendiculat assays suggested that XRF may reduce uptake of MTX by down-regulating reduced folate carrier 1 (RFC1).This study indicated that XRF could reduce the plasma concentration of MTX by inhibiting the expression of RFC1, antagonize the therapeutic effect of MTX on AIA rats, and reduce its oral bioavailability. The combination of |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
